Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02455076 · ClinicalTrials.gov registry record · Phase 4
Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes
A Phase 4 study of Type 2 Diabetes, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
- 2
- Study locations
NCT02455076 is a Phase 4 study of Type 2 Diabetes that has completed, run by Emory University. The registered enrollment target is 150 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT02455076, a Phase 4 study of Type 2 Diabetes, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to try and achieve similar glycemic control in general non-Intensive Care Unit (non-ICU) patients with Type 2 Diabetes with exenatide alone or in combination with basal insulin as compared to treatment with basal bolus insulin alone. The association between hyperglycemia and poor clinical outcomes in patients with diabetes is well established. Previous studies have shown that basal bolus insulin regimens improve glycemic control and reduce the rate of hospital complications compared to sliding scale regular insulin (SSRI) therapy, but has a significant risk of hypoglycemia. The investigators will compare the efficacy and safety of exenatide alone or in combination with basal insulin to control high blood glucose levels resulting in a lower risk of hypoglycemia.
Conditions Studied
Interventions
- DRUG Exenatide
- DRUG Glargine
- DRUG Rapid-acting insulin analogs
Study Locations (2)
Georgia
- Grady Memorial Hospital - Atlanta
- Emory University Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2015-09 |
| Est. Completion | 2018-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02455076
The ClinicalTrials.gov registry entry for NCT02455076 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (86% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Exenatide is the first listed.
NCT02455076 reports 2 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT02455076 about?
NCT02455076 is a clinical study titled "Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes". The purpose of this study is to try and achieve similar glycemic control in general non-Intensive Care Unit (non-ICU) patients with Type 2 Diabetes with exenatide alone or in combination with basal insulin as compared to treatment with basal bolus insulin alone. The association between hyperglycemia...
What is the current status of trial NCT02455076?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2015-09. Estimated completion is 2018-03.
What conditions does trial NCT02455076 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT02455076?
The interventions under investigation include: Exenatide (DRUG), Glargine (DRUG), Rapid-acting insulin analogs (DRUG).
Who is sponsoring clinical trial NCT02455076?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02455076 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanism of SGLT2 Inhibition in the Kidney
RECRUITING · Phase 4
-
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
RECRUITING · Phase 4
-
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes
RECRUITING · Phase 4
-
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
RECRUITING · Phase 4
-
Quantifying Hepatic Mitochondrial Fluxes in Humans
RECRUITING · Phase 4
-
DIALYSIS-TIR Study
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.